StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Quarter

Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — U.S. reported YoY (%) (%)

QuarterlyAnnual

Pfizer Braftovi + Mektovi (encorafenib / binimetinib: 21.0% in Q2 2026, unchanged from a year earlier.

Latest, Q2 2026
21.0%
Period ended Jun 28, 2026
Change on a year earlier
0.0 pts
21.0% in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Braftovi/Mektovi | 223 | 182 | 23% | 23% | 208 | 171 | 21% | 16 | 10 | 54% | 48%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBraftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — U.S. reported YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 202621.0%0.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202625.0%+10.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202512.0%-14.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202515.0%-16.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202521.0%-8.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202515.0%+4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 202426.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 202431.0%–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202429.0%–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202411.0%–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗

Cite this data

StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.